BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 15608473)

  • 1. Renal cell carcinoma: the experience of Kuwait Cancer Control Center, Kuwait.
    Thotathil ZS; Varghese A; Ragheb A
    Med Princ Pract; 2005; 14(1):1-5. PubMed ID: 15608473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials.
    Leibovich BC; Han KR; Bui MH; Pantuck AJ; Dorey FJ; Figlin RA; Belldegrun A
    Cancer; 2003 Dec; 98(12):2566-75. PubMed ID: 14669275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
    Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
    J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy.
    Naitoh J; Kaplan A; Dorey F; Figlin R; Belldegrun A
    J Urol; 1999 Jul; 162(1):46-50. PubMed ID: 10379737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant immunotherapy in renal cell carcinoma--comparison of interferon alpha treatment with an untreated control.
    Basting R; Corvin S; Händel D; Hinke A; Schmidt D
    Anticancer Res; 1999; 19(2C):1545-8. PubMed ID: 10365142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients.
    Figlin R; Gitlitz B; Franklin J; Dorey F; Moldawer N; Rausch J; deKernion J; Belldegrun A
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S92-7. PubMed ID: 9457402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
    Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
    Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC
    Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy.
    Itano NB; Blute ML; Spotts B; Zincke H
    J Urol; 2000 Aug; 164(2):322-5. PubMed ID: 10893575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinoma.
    Belldegrun A; Shvarts O; Figlin RA
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S88-92. PubMed ID: 10685666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Local recurrence of renal cell carcinoma after nephrectomy].
    Pereverzev AS; Shchukin DV; Iliukhin IuA
    Urologiia; 2003; (6):14-8. PubMed ID: 14708237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of bilaterality, pathological features and surgical outcome in nonhereditary renal cell carcinoma.
    Blute ML; Itano NB; Cheville JC; Weaver AL; Lohse CM; Zincke H
    J Urol; 2003 Apr; 169(4):1276-81. PubMed ID: 12629342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal cell carcinoma with renal vein and inferior vena caval involvement: clinicopathological features, surgical techniques and outcomes.
    Parekh DJ; Cookson MS; Chapman W; Harrell F; Wells N; Chang SS; Smith JA
    J Urol; 2005 Jun; 173(6):1897-902. PubMed ID: 15879771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal sinus fat invasion in pT3a clear cell renal cell carcinoma affects outcomes of patients without nodal involvement or distant metastases.
    Bertini R; Roscigno M; Freschi M; Strada E; Petralia G; Pasta A; Matloob R; Sozzi F; Da Pozzo L; Colombo R; Guazzoni G; Doglioni C; Montorsi F; Rigatti P
    J Urol; 2009 May; 181(5):2027-32. PubMed ID: 19286201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal cell carcinoma with tumor thrombus extension into the vena cava: prospective long-term followup.
    Haferkamp A; Bastian PJ; Jakobi H; Pritsch M; Pfitzenmaier J; Albers P; Hallscheidt P; Müller SC; Hohenfellner M
    J Urol; 2007 May; 177(5):1703-8. PubMed ID: 17437789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general population.
    Neuzillet Y; Tillou X; Mathieu R; Long JA; Gigante M; Paparel P; Poissonnier L; Baumert H; Escudier B; Lang H; Rioux-Leclercq N; Bigot P; Bernhard JC; Albiges L; Bastien L; Petit J; Saint F; Bruyere F; Boutin JM; Brichart N; Karam G; Branchereau J; Ferriere JM; Wallerand H; Barbet S; Elkentaoui H; Hubert J; Feuillu B; Theveniaud PE; Villers A; Zini L; Descazeaux A; Roupret M; Barrou B; Fehri K; Lebret T; Tostain J; Terrier JE; Terrier N; Martin L; Dugardin F; Galliot I; Staerman F; Azemar MD; Irani J; Tisserand B; Timsit MO; Sallusto F; Rischmann P; Guy L; Valeri A; Deruelle C; Azzouzi AR; Chautard D; Mejean A; Salomon L; Rigaud J; Pfister C; Soulié M; Kleinclauss F; Badet L; Patard JJ; ;
    Eur Urol; 2011 Aug; 60(2):366-73. PubMed ID: 21377780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy.
    Pantuck AJ; Zisman A; Dorey F; Chao DH; Han KR; Said J; Gitlitz B; Belldegrun AS; Figlin RA
    Cancer; 2003 Jun; 97(12):2995-3002. PubMed ID: 12784334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience.
    Franklin JR; Figlin R; Rauch J; Gitlitz B; Belldegrun A
    Semin Urol Oncol; 1996 Nov; 14(4):230-6. PubMed ID: 8946623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcomes after maximal surgical resection and intraoperative electron radiotherapy for locoregionally recurrent or locoregionally advanced primary renal cell carcinoma.
    Hallemeier CL; Choo R; Davis BJ; Pisansky TM; Gunderson LL; Leibovich BC; Haddock MG
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1938-43. PubMed ID: 21514065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant interferon alpha therapy in renal cell carcinoma (RCC): prognostic value of DNA cytophotometry.
    Basting R; Corvin S; Händel D; Hinke A; Schmidt D
    Anticancer Res; 1999; 19(2C):1493-5. PubMed ID: 10365130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.